603590 Stock Overview
Engages in the research and development, production, and sale of pharmaceuticals in China and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 3/6 |
Past Performance | 4/6 |
Financial Health | 5/6 |
Dividends | 3/6 |
Beijing Konruns Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥25.50 |
52 Week High | CN¥41.95 |
52 Week Low | CN¥22.46 |
Beta | 0.36 |
11 Month Change | 3.53% |
3 Month Change | -16.58% |
1 Year Change | -24.04% |
33 Year Change | -24.24% |
5 Year Change | -29.89% |
Change since IPO | -27.25% |
Recent News & Updates
Recent updates
Shareholder Returns
603590 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | 6.1% | -1.1% | -0.6% |
1Y | -24.0% | -11.9% | -19.0% |
Return vs Industry: 603590 underperformed the CN Pharmaceuticals industry which returned -11.9% over the past year.
Return vs Market: 603590 underperformed the CN Market which returned -19% over the past year.
Price Volatility
603590 volatility | |
---|---|
603590 Average Weekly Movement | 4.3% |
Pharmaceuticals Industry Average Movement | 5.2% |
Market Average Movement | 5.6% |
10% most volatile stocks in CN Market | 8.9% |
10% least volatile stocks in CN Market | 3.7% |
Stable Share Price: 603590's share price has been volatile over the past 3 months.
Volatility Over Time: 603590's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 447 | Jianhua Liu | www.konruns.cn |
Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon acutus hemocoagulase under Suling trade name, a single-component hemocoagulase clinical hemostatic drug for surgical operations.
Beijing Konruns Pharmaceutical Co.,Ltd. Fundamentals Summary
603590 fundamental statistics | |
---|---|
Market cap | CN¥3.83b |
Earnings (TTM) | CN¥166.44m |
Revenue (TTM) | CN¥954.14m |
24.4x
P/E Ratio4.2x
P/S RatioIs 603590 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
603590 income statement (TTM) | |
---|---|
Revenue | CN¥954.14m |
Cost of Revenue | CN¥105.92m |
Gross Profit | CN¥848.23m |
Other Expenses | CN¥681.79m |
Earnings | CN¥166.44m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 28, 2024
Earnings per share (EPS) | 1.05 |
Gross Margin | 88.90% |
Net Profit Margin | 17.44% |
Debt/Equity Ratio | 5.1% |
How did 603590 perform over the long term?
See historical performance and comparison